Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Gao, Ju ^a   Yin, Minzhi ^b   Zhu, Yiping ^a   Gu, Ling ^a   Zhang, Yanle ^a   Li, Qiang ^a   Jia, Cangsong ^a   Ma, Zhigui ^a  

^a SICHUAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

4E BP1; AKT; Anaplastic large cell lymphoma (ALCL); Anaplastic lymphoma kinase (ALK); mTOR; p 70S6K1; Prognosis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CYTOKINE; GLUCOCORTICOID; HYBRID PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOPROTEIN; PROTEIN KINASE B; S6 KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RESISTANCE; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN VITRO STUDY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MICE; MIDDLE AGED; PHOSPHOPROTEINS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84885136376     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-471     Document Type: Article

References (39)

1. Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, Delsol G, Mason D. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997, 89:1394-1404.
2. Morris SW, Xue L, Ma Z, Kinney MC. Alk + CD30+ lymphomas: a distinct molecular Genetic subtype of non-hodgin lymphoma. Br J Hematol 2001, 113:275-295.
3. Lamant L, Dastugue N, Pulford K, Delsol G, Mariamé B. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999, 93:3088-3095.
4. Ma ZG, Cools J, Marynen P, Cui XL, Siebert R, Gesk S, Schlegelberger B, Peeters B, Wolf-Peeters CD, Wlodarska I, Morris SW. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000, 95:2144-2149.
5. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008, 8:11-23. 10.1038/nrc2291, 18097461.
6. Feldman AL, Vasmatzis G, Asmann YW, Davila J, Middha S, Eckloff BW, Johnson SH, Porcher JC, Ansell SM, Caride A. Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. Genes Chromosomes Cancer 2013, 52:1097-1102.
7. Cessna MH, Zhou H, Sanger WG, Perkins SL, Tripp S, Pickering D, Daines C, Coffin CM. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol 2002, 15:931-938. 10.1097/01.MP.0000026615.04130.1F, 12218210.
8. Jazii FR, Najafi Z, Malekzadeh R, Conrads TP, Ziaee AA, Abnet C, Yazdznbod M, Karkhane AA, Salekdeh GH. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 2006, 12:7104-7112.
9. Soda M, Choi YL, Enomoto M, Takade S, Yamashita Y, Ishikawa S, Fujiwara SI, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566. 10.1038/nature05945, 17625570.
10. Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, Kwee I, Bertoni F, Piccaluga PP, Pileri SA, Inghirami G. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 2011, 47:R11-R23. 10.1530/JME-11-0004, 21502284.
11. Takeuchi K, Soda M, Togashi Y, Ota Y, Sekiguchi Y, Hetano S, Asaka R, Noguchi M, Mano H. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 2011, 96:464-467. 10.3324/haematol.2010.033514, 3046280, 21134980.
12. Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997, 17:2312-2325. 232080, 9121481.
13. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugières L, Terrier-Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris SW, Mason DY, Delsol G. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998, 91:2076-2084.
14. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999, 93:2697-2706.
15. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A, Weisenburger DD. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large-cell lymphoma. Blood 1999, 93:3913-3921.
16. Sandlund JT, Pui CH, Roberts WM, Santana VM, Morris SW, Berard CW, Hutchison RE, Ribeiro RC, Mahmoud H, Crist WM. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood 1994, 84:2467-2471.
17. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, Mori N, Fujimoto J, Miyauchi J, Mikata A. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995, 86:1954-1960.
18. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol 2013, 85:293-302.
19. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-negative. Crit Rev Oncol Hematol 2013, 85:206-215. 10.1016/j.critrevonc.2012.06.004, 22789917.
20. Li RS, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 2008, 28:372-412. 10.1002/med.20109, 17694547.
21. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007, 110:2259-2267. 10.1182/blood-2007-04-060715, 1988960, 17519389.
22. Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 2007, 26:5606-5614. 10.1038/sj.onc.1210346, 17353907.
23. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006, 66:6589-6597. 10.1158/0008-5472.CAN-05-3018, 16818631.
24. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Thomas Look A. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in Non-Hodgkin's lymphoma. Science 1994, 263:1281-1284. 10.1126/science.8122112, 8122112.
25. Falini B, Pulford K, Pucciarini A, Carbone A, Wolf-Peeters CD, Cordell J, Fizzotti M, Santucci A, Pelicci PG, Pileri S, Campo E, Ott G, Delsol G, Mason DY. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 1999, 94:3509-3515.
26. Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, Carbone A, Paulli M, Magrini U, Menestrina F, Giardini R, Pilotti S, Mezzelani A, Ugolinl B, Billi M, Pucciarini A, Pacini R, Pelicci PG, Flenghi L. ALK expression defines a distinct group of T/null lymphomas (" ALK lymphomas") with a wide morphological spectrum. Am J Pathol 1998, 153:875-886. 10.1016/S0002-9440(10)65629-5, 1853018, 9736036.
27. Wang FH, Li YH, Zeng J, Rao HL, Xia ZJ, Sun XF, Huang HQ, Lin TY, Jiang WQ, Guan ZZ. Clinical analysis of primary systemic anaplastic large cell lymphoma: a report of 57 cases. Chin J Cancer 2009, 28:49-53.
28. Lim MS, Carlson ML, Crockett DK, Fillmore GC, Abbott DR, Elenitoba-Johnson OF, Tripp SR, Rassidakis GZ, Medeiors LJ, Szankasi P, Elenitoba-Johnson KSJ. The proteomic signature of NPM-ALK reveals deregulation of multiple cellular pathways. Blood 2009, 114:1585-1595. 10.1182/blood-2009-02-204735, 19531656.
29. Lee DF, Hung MC. All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle 2007, 6:3011-3014. 10.4161/cc.6.24.5085, 18073529.
30. Albanell J, Dalmases A, Rovira A, Rojo F. mTOR signaling in human cancer. Clin Transl Oncol 2007, 9:484-493. 10.1007/s12094-007-0092-6, 17720651.
31. Seelinger H, Guba M, Kleespies A, Jauch KW, Bruns CJ. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastasis, and angiogenesis. Cancer Metastasis Rev 2007, 26:611-621. 10.1007/s10555-007-9077-8, 17713840.
32. Ghayad SE, Cohen PA. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov 2010, 5:29-57. 10.2174/157489210789702208, 19751211.
33. Awada A, Cardoso F, Fontaine C, Dirix L, Grève JD, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Zoellner U, Tang P, Piccart M. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. Eur J Cancer 2008, 44:84-91. 10.1016/j.ejca.2007.10.003, 18039566.
34. Akcakanat A, Zhang L, Tsavachidis S, Meric-Bernstam F. The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Mol Cancer 2009, 8:75. 2761377, 19778445.
35. Petricoin EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ, Qualman S, Tsokos M, Krishnan K, Helman LJ, Liotta LA. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. Cancer Res 2007, 67:3431-3440. 10.1158/0008-5472.CAN-06-1344, 17409454.
36. Pelloski CE, Lin E, Zhang L, Alfred Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG, Fuller GN, Aldape KD. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 2006, 12:3935-3941. 10.1158/1078-0432.CCR-05-2202, 16818690.
37. Noh WC, Kim YH, Kim MS, Koh JS, Kim HA, Moon NM, Paik NS. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat 2008, 110:447-483.
38. Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 2010, 1:89-103. 2911128,2911128, 20671809.
39. Gu L, Gao J, Li Q, Zhu YP, Jia CS, Fu RY, Chen Y, Liao QK, Ma ZG. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. Leukemia 2008, 22:2091-2096. 10.1038/leu.2008.204, 18685609.